Condition: HIV-1-infection · Sponsor: University of Nairobi
The goal of this study is to address the gap in published data on viral suppression among people meeting the criteria for virologic failure on dolutegravir (DTG)-based ART regimens without a change in regimen. The study will also assess the emergence of DTG-associated drug-resistant mutations and their impact on viral suppression.
This description comes directly from the study's public registry record.
Joseph Nkuranga, MBChB, MSc · +254737223988 · dnkuranga@uonbi.ac.ke
Always discuss trial participation with your own doctor first.
| Jaramogi Oginga Odinga Teaching and Referral Hospital | Kisumu, Kenya | Recruiting |
| Bomu Hospital | Mombasa, Kenya | Not Yet Recruiting |
| Kenyatta National Hospital | Nairobi, Kenya | Recruiting |
| Butha-Buthe District Hospital | Butha-Buthe, Lesotho | Recruiting |
| Mokhotlong District Hospital | Mokhotlong, Lesotho | Recruiting |
| CS Ponta Gea | Beira, Sofala, Mozambique | Not Yet Recruiting |
| CS Machava II | Maputo, Mozambique | Not Yet Recruiting |
| CS Ndlavela | Maputo, Mozambique | Not Yet Recruiting |
| MUHAS Clinical Trial Unit | Dar es Salaam, Tanzania | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06762054